Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 1/20 | 0.49 |
| ▸ | PPARA | Q07869 | 2/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | KCNH3 | Q9ULD8 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.46 |
| ▸ | CNR2 | P34972 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6692354 | 0.87 | PPARA (0.54) | MEN1KMT2AMAPTMAOBPPARA | |
| SCHEMBL1965560 | 0.84 | FFAR1 (0.51) | EGFRMEN1KMT2A | |
| SCHEMBL11510710 | 0.81 | FFAR1 (0.57) | EGFRMEN1KMT2AMAPT | |
| SCHEMBL4927105 | 0.80 | MAPT (0.45) | EGFRMEN1KMT2AMAPTATM | |
| SCHEMBL6695962 | 0.80 | AGER (0.58) | EGFRMEN1KMT2AMAPTPPARA | |
| SCHEMBL10055035 | 0.80 | HPGD (0.67) | MEN1KMT2AMAPTPPARAHPGD | |
| SCHEMBL5452615 | 0.79 | MAOB (0.64) | MEN1KMT2AMAPTMAOBPPARA | |
| SCHEMBL5998792 | 0.79 | FLT1 (0.55) | EGFRMAPTKCNH3 | |
| SCHEMBL14808999 | 0.79 | MAPT (0.67) | EGFRMEN1KMT2AMAPTPPARA | |
| SCHEMBL1241386 | 0.79 | CA1 (0.48) | EGFRMEN1KMT2AMAOBPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227648-A1 | PYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF CANCER | ASTRAZENECA AB | 2009-09-10 | — | — | US | disclosed |
| EP-1742921-A2 | PYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF CANCER | AstraZeneca AB (SE) | 2007-01-17 | — | — | EP | disclosed |
| WO-2005103010-A2 | PYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2005-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227648-A1 | PYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF CANCER | TP53, PDK2, PDK1 | EGFR 1343/4885MEN1 2566/4885KMT2A 2817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.